{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T03:47:26Z","timestamp":1788752846437,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,20]],"date-time":"2022-11-20T00:00:00Z","timestamp":1668902400000},"content-version":"am","delay-in-days":323,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35 GM122462"],"award-info":[{"award-number":["R35 GM122462"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006151","name":"Basic Energy Sciences","doi-asserted-by":"publisher","award":["S10_RR028976"],"award-info":[{"award-number":["S10_RR028976"]}],"id":[{"id":"10.13039\/100006151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006151","name":"Basic Energy Sciences","doi-asserted-by":"publisher","award":["S10_RR25528"],"award-info":[{"award-number":["S10_RR25528"]}],"id":[{"id":"10.13039\/100006151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006151","name":"Basic Energy Sciences","doi-asserted-by":"publisher","award":["W-31-109-Eng-38"],"award-info":[{"award-number":["W-31-109-Eng-38"]}],"id":[{"id":"10.13039\/100006151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006224","name":"Argonne National Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Biology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jmb.2021.167349","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T11:03:48Z","timestamp":1636542228000},"page":"167349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Imatinib can act as an Allosteric Activator of Abl Kinase"],"prefix":"10.1016","volume":"434","author":[{"given":"Tao","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamjeed","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darcie","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos G.","family":"Kalodimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmb.2021.167349_b0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","article-title":"Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?","volume":"14","author":"Rosti","year":"2017","journal-title":"Nature Rev. Clin. Oncol."},{"key":"10.1016\/j.jmb.2021.167349_b0010","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jmb.2021.167349_b0015","doi-asserted-by":"crossref","first-page":"eabc2754","DOI":"10.1126\/science.abc2754","article-title":"Conformational states dynamically populated by a kinase determine its function","volume":"370","author":"Xie","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jmb.2021.167349_b0020","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2021.167349_b0025","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jmb.2021.167349_b0030","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jmb.2021.167349_b0035","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/cncr.28522","volume":"120","author":"Soverini","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jmb.2021.167349_b0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MOH.0000000000000403","article-title":"Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents","volume":"25","author":"Talati","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.jmb.2021.167349_b0045","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer cell"},{"key":"10.1016\/j.jmb.2021.167349_b0050","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature14119","article-title":"Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation","volume":"519","author":"Pemovska","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2021.167349_b0055","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00277-016-2820-x","article-title":"Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion","volume":"96","author":"Breccia","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jmb.2021.167349_b0060","first-page":"1","article-title":"Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives","volume":"8","author":"Anagnostou","year":"2018","journal-title":"Blood Lymphat Cancer"},{"key":"10.1016\/j.jmb.2021.167349_b0065","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s12185-014-1566-2","article-title":"Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study","volume":"99","author":"Baccarani","year":"2014","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.jmb.2021.167349_b0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.12618","article-title":"Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia","volume":"164","author":"Deininger","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jmb.2021.167349_b0075","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jmb.2021.167349_b0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nchembio760","article-title":"Allosteric inhibitors of Bcr-abl-dependent cell proliferation","volume":"2","author":"Adri\u00e1n","year":"2006","journal-title":"Nature Chem. Biol."},{"key":"10.1016\/j.jmb.2021.167349_b0085","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2021.167349_b0090","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2021.167349_b0095","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","article-title":"Structural basis for the autoinhibition of c-Abl tyrosine kinase","volume":"112","author":"Nagar","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2021.167349_b0100","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nsmb.3470","article-title":"Atomic view of the energy landscape in the allosteric regulation of Abl kinase","volume":"24","author":"Saleh","year":"2017","journal-title":"Nature Struct. Mol. Biol."},{"key":"10.1016\/j.jmb.2021.167349_b0105","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.1021\/ja101837n","article-title":"Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay","volume":"132","author":"Jahnke","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jmb.2021.167349_b0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chembiol.2010.12.013","article-title":"Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site","volume":"18","author":"Yang","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.jmb.2021.167349_b0115","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jmb.2021.167349_b0120","doi-asserted-by":"crossref","first-page":"18292","DOI":"10.1074\/jbc.M801337200","article-title":"Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib\/nilotinib and dasatinib","volume":"283","author":"Vajpai","year":"2008","journal-title":"J. Bio. Chem."},{"key":"10.1016\/j.jmb.2021.167349_b0125","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nsmb.2891","article-title":"Energetic dissection of Gleevec's selectivity toward human tyrosine kinases","volume":"21","author":"Agafonov","year":"2014","journal-title":"Nature Struct. Mol. Biol."},{"key":"10.1016\/j.jmb.2021.167349_b0130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1073\/pnas.0811223106","article-title":"A conserved protonation-dependent switch controls drug binding in the Abl kinase","volume":"106","author":"Shan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jmb.2021.167349_b0135","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1021\/jm101506n","article-title":"Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class","volume":"54","author":"Salah","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2021.167349_b0140","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cell.2011.08.046","article-title":"Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis","volume":"147","author":"Grebien","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2021.167349_b0145","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1101\/gad.13.18.2400","article-title":"cAbl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF","volume":"13","author":"Plattner","year":"1999","journal-title":"Genes. Dev."},{"key":"10.1016\/j.jmb.2021.167349_b0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/13543784.2011.546344","article-title":"Mechanisms of drug resistance in kinases","volume":"20","author":"Barouch-Bentov","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jmb.2021.167349_b0155","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.13966","article-title":"Present and future of molecular monitoring in chronic myeloid leukaemia","volume":"173","author":"Soverini","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jmb.2021.167349_b0160","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jmb.2021.167349_b0165","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jmb.2021.167349_b0170","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2021.167349_b0175","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5966\/sctm.2012-0159","article-title":"Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors","volume":"3","author":"Ichim","year":"2014","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.jmb.2021.167349_b0180","first-page":"E4437","article-title":"NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors","author":"Skrora","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jmb.2021.167349_b0185","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1021\/jacs.7b12430","article-title":"ATP site ligands determine the assembly state of the Abelson kinase regulatory core via the activation loop conformation","volume":"140","author":"Sonti","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jmb.2021.167349_b0190","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nchembio.1981","article-title":"Cyclophilin A promotes cell migration via the Abl-Crk signaling pathway","volume":"12","author":"Saleh","year":"2016","journal-title":"Nature Chem. Biol."},{"key":"10.1016\/j.jmb.2021.167349_b0195","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nchembio.494","article-title":"Structural basis for regulation of the Crk signaling protein by a proline switch","volume":"7","author":"Sarkar","year":"2011","journal-title":"Nature Chem. Biol."},{"key":"10.1016\/j.jmb.2021.167349_b0200","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10858-016-0041-1","article-title":"Exploiting E. coli auxotrophs for leucine, valine, and threonine specific methyl labeling of large proteins for NMR applications","volume":"65","author":"Monneau","year":"2016","journal-title":"J. Biomol. NMR"},{"key":"10.1016\/j.jmb.2021.167349_b0205","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1126\/science.aax1280","article-title":"Structural basis for client recognition and activity of Hsp40 chaperones","volume":"365","author":"Jiang","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jmb.2021.167349_b0210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/bs.mie.2018.08.036","article-title":"Toolkit for NMR studies of methyl-labeled proteins","volume":"614","author":"Rossi","year":"2019","journal-title":"Meth. Enzymol."},{"key":"10.1016\/j.jmb.2021.167349_b0215","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00197809","article-title":"NMRPipe: a multidimensional spectral processing system based on UNIX pipes","volume":"6","author":"Delaglio","year":"1995","journal-title":"J. Biomol. NMR"},{"key":"10.1016\/j.jmb.2021.167349_b0220","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/bioinformatics\/btu830","article-title":"NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy","volume":"31","author":"Lee","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jmb.2021.167349_b0225","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10858-016-0074-5","article-title":"15N and 13C- SOFAST-HMQC editing enhances 3D-NOESY sensitivity in highly deuterated, selectively [1H,13C]-labeled proteins","volume":"66","author":"Rossi","year":"2016","journal-title":"J. Biomol. NMR"},{"key":"10.1016\/j.jmb.2021.167349_b0230","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10858-017-0149-y","article-title":"Automatic methyl assignment in large proteins by the MAGIC algorithm","volume":"69","author":"Monneau","year":"2017","journal-title":"J. Biomol. NMR"},{"key":"10.1016\/j.jmb.2021.167349_b0235","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1107\/S0907444909047374","article-title":"Integration, scaling, space-group assignment and post-refinement","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"10.1016\/j.jmb.2021.167349_b0240","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1107\/S0907444913000061","article-title":"How good are my data and what is the resolution?","volume":"69","author":"Evans","year":"2013","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"10.1016\/j.jmb.2021.167349_b0245","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.jmb.2021.167349_b0250","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"10.1016\/j.jmb.2021.167349_b0255","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1107\/S0907444996012255","article-title":"Refinement of macromolecular structures by the maximum-likelihood method","volume":"53","author":"Murshudov","year":"1997","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"10.1016\/j.jmb.2021.167349_b0260","doi-asserted-by":"crossref","first-page":"8148","DOI":"10.1021\/ja3001419","article-title":"Studying \u201cinvisible\u201d excited protein states in slow exchange with a major state conformation","volume":"134","author":"Vallurupalli","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jmb.2021.167349_b0265","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10858-015-9974-z","article-title":"(13)CHD2-CEST NMR spectroscopy provides an avenue for studies of conformational exchange in high molecular weight proteins","volume":"63","author":"Rennella","year":"2015","journal-title":"J. Biomol. NMR"},{"key":"10.1016\/j.jmb.2021.167349_b0270","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/ja067827z","article-title":"Probing side-chain dynamics in the proteasome by relaxation violated coherence transfer NMR spectroscopy","volume":"129","author":"Tugarinov","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jmb.2021.167349_b0275","doi-asserted-by":"crossref","first-page":"14878","DOI":"10.1021\/jp209049k","article-title":"An optimized relaxation-based coherence transfer NMR experiment for the measurement of side-chain order in methyl-protonated, highly deuterated proteins","volume":"115","author":"Sun","year":"2011","journal-title":"J. Phys. Chem. B"}],"container-title":["Journal of Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022283621005866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022283621005866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T06:22:41Z","timestamp":1762669361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022283621005866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0022283621005866"],"URL":"https:\/\/doi.org\/10.1016\/j.jmb.2021.167349","relation":{},"ISSN":["0022-2836"],"issn-type":[{"value":"0022-2836","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imatinib can act as an Allosteric Activator of Abl Kinase","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmb.2021.167349","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"167349"}}